FDA approves Merck's LIPFENDRA, first oral PCSK9 inhibitor to lower LDL cholesterol.

FDA approves Merck's first oral PCSK9 inhibitor pill for lowering cholesterol, expanding treatment options.

The US FDA has approved Merck's Lipfendra, the first oral PCSK9 inhibitor pill designed to lower LDL cholesterol in patients with hypercholesterolemia, including hereditary cases. This pill offers a new alternative to injectable drugs, potentially in...